+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Endocrine Management of Advanced Breast Cancer

      a , b

      Hormone Research in Paediatrics

      S. Karger AG

      Advanced breast cancer, Endocrine therapy, Tamoxifen, Combined therapies

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Recent research has produced several new options for endocrine treatment of advanced breast cancer. Since one of the most intriguing characteristics of endocrine therapy is that new remissions are possible when subsequent endocrine modalities are used, it is important to evaluate their optimal sequence. Tamoxifen has become the most commonly used endocrine therapy for advanced breast cancer due to its few side effects and an overall response rate of 35%. Crossover data from randomised trials, comparing tamoxifen with either ablative, additive or inhibitive treatment, indicate that the highest overall response rate is obtained when tamoxifen is used as first-line endocrine therapy. Furthermore, it seems that oophorectomy in premenopausal, and aminoglutethimide or progestins in postmenopausal patients, are equally effective as second-line endocrine therapy. Despite an obvious clinical rationale for combined endocrine therapy, most trials have failed to show any benefit. Although data from trials combining tamoxifen with prednisolone or androgens seem promising, the use of combined endocrine therapy still has to be considered experimental.■

          Related collections

          Author and article information

          Horm Res Paediatr
          Hormone Research in Paediatrics
          S. Karger AG
          02 December 2008
          : 32
          : Suppl 1
          : 189-197
          aDepartment of Oncology R, Odense University Hospital Odense and bDepartment of Oncology ONA The Finsen Institute/Rigshospitalet, Copenhagen, Denmark
          181344 Horm Res 1989;32:189–197
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9
          Breast Cancer


          Comment on this article